Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature.

Reijnders MRF, Janowski R, Alvi M, Self JE, van Essen TJ, Vreeburg M, Rouhl RPW, Stevens SJC, Stegmann APA, Schieving J, Pfundt R, van Dijk K, Smeets E, Stumpel CTRM, Bok LA, Cobben JM, Engelen M, Mansour S, Whiteford M, Chandler KE, Douzgou S, Cooper NS, Tan EC, Foo R, Lai AHM, Rankin J, Green A, Lönnqvist T, Isohanni P, Williams S, Ruhoy I, Carvalho KS, Dowling JJ, Lev DL, Sterbova K, Lassuthova P, Neupauerová J, Waugh JL, Keros S, Clayton-Smith J, Smithson SF, Brunner HG, van Hoeckel C, Anderson M, Clowes VE, Siu VM, Ddd Study T, Selber P, Leventer RJ, Nellaker C, Niessing D, Hunt D, Baralle D.

J Med Genet. 2018 Feb;55(2):104-113. doi: 10.1136/jmedgenet-2017-104946. Epub 2017 Nov 2.

2.

The genetics of Leigh syndrome and its implications for clinical practice and risk management.

Ruhoy IS, Saneto RP.

Appl Clin Genet. 2014 Nov 13;7:221-34. doi: 10.2147/TACG.S46176. eCollection 2014. Review.

3.

Cystathionine beta-synthase deficiency heralded by cerebral sinus venous thrombosis and stroke.

Ruhoy IS, Merritt JL 2nd, Amlie-Lefond C.

Pediatr Neurol. 2014 Jan;50(1):108-11. doi: 10.1016/j.pediatrneurol.2013.08.021. Epub 2013 Oct 15.

PMID:
24138954
4.

Lower-dose prescribing: minimizing "side effects" of pharmaceuticals on society and the environment.

Daughton CG, Ruhoy IS.

Sci Total Environ. 2013 Jan 15;443:324-37. doi: 10.1016/j.scitotenv.2012.10.092. Epub 2012 Nov 29.

5.

Green pharmacy and pharmEcovigilance: prescribing and the planet.

Daughton CG, Ruhoy IS.

Expert Rev Clin Pharmacol. 2011 Mar;4(2):211-32. doi: 10.1586/ecp.11.6. Review.

PMID:
22115404
6.

Environmental footprint of pharmaceuticals: the significance of factors beyond direct excretion to sewers.

Daughton CG, Ruhoy IS.

Environ Toxicol Chem. 2009 Dec;28(12):2495-521. doi: 10.1897/08-382.1. Epub 2009 Apr 21. Review.

PMID:
19382823
7.

Disposal practices for unwanted residential medications in the United States.

Glassmeyer ST, Hinchey EK, Boehme SE, Daughton CG, Ruhoy IS, Conerly O, Daniels RL, Lauer L, McCarthy M, Nettesheim TG, Sykes K, Thompson VG.

Environ Int. 2009 Apr;35(3):566-72. doi: 10.1016/j.envint.2008.10.007. Epub 2008 Dec 10. Review.

PMID:
19081631
8.

The afterlife of drugs and the role of pharmEcovigilance.

Daughton CG, Ruhoy IS.

Drug Saf. 2008;31(12):1069-82. doi: 10.2165/0002018-200831120-00004.

PMID:
19026025
9.

Beyond the medicine cabinet: an analysis of where and why medications accumulate.

Ruhoy IS, Daughton CG.

Environ Int. 2008 Nov;34(8):1157-69. doi: 10.1016/j.envint.2008.05.002. Epub 2008 Jun 20.

PMID:
18571238
10.

Types and quantities of leftover drugs entering the environment via disposal to sewage--revealed by coroner records.

Ruhoy IS, Daughton CG.

Sci Total Environ. 2007 Dec 15;388(1-3):137-48. Epub 2007 Sep 20.

PMID:
17888494

Supplemental Content

Support Center